This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Stephanie J. Bird, PhD

JAMA. 1985;253(22):3286-3291.

Abstract
Recombinant DNA technology has made possible the identification of a DNA marker for Huntington's disease (HD). In spite of limitations to a presymptomatic test based on this work, and a variety of ethical and policy concerns associated with presymptomatic testing in general, it is likely that such a testing program can and will soon be developed. Its impact needs to be carefully considered by the health care community and policymakers. A presymptomatic test for HD is sought by those at risk and should be made available with proper safeguards to protect confidentiality. Given its potential impact, testing should be offered in a setting that provides diverse and continuing support. Research institutions with a variety of counseling programs, health care professionals, HD lay organizations, and society at large can work together to develop programs that provide the support necessary for responsible, autonomous decision making.

(JAMA 1985;253:3286-3291)

Author Affiliations
From the Science, Technology, and Society Program and the Center for Policy Alternatives, Massachusetts Institute of Technology, Cambridge.

Footnotes
Reprint requests to Massachusetts Institute of Technology, E40-219, Cambridge, MA 02139 (Dr Bird).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Molecular Genetic Revolution: Its Impact on Clinical Neurology
Payne and Roses
Arch Neurol 1988;45:1366-1376.
ABSTRACT